Multiple sclerosis associates with LILRA3 deletion in Spanish patients

Genes and Immunity

Volumn 10, Issue 6, 2009, Pages 579-585

  Ordonez D ^a   Sanchez A J ^a   Martinez Rodriguez J E ^b   Cisneros, E ^a   Ramil, E ^a   Romo, N ^c   Moraru, M ^a   Munteis, E ^b   Lopez Botet M ^c   Roquer, J ^b   Garcia Merino A ^a   Vilches, C ^a  

^a HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^b HOSPITAL DEL MAR   (Spain)

^c UNIVERSITAT POMPEU FABRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE RECEPTOR; HLA DR ANTIGEN; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; LEUKOCYTE IMMUNOGLOBULIN LIKE RECEPTOR FAMILY A3; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ALLELE; ARTICLE; AUTOIMMUNITY; CHILD; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; GENE DELETION; GENE DOSAGE; GENE FUNCTION; GENE INTERACTION; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC EPISTASIS; GENETIC SUSCEPTIBILITY; GENETIC TRAIT; GENETIC VARIABILITY; GENOTYPE; GERMANY; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; IMMUNOPATHOGENESIS; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; RELAPSE; SCHOOL CHILD; SPAIN; TELOMERE;

ADOLESCENT; ADULT; AGED; CASE-CONTROL STUDIES; CHILD; FEMALE; GENE DELETION; GENETIC VARIATION; GENOTYPE; HLA-DR ANTIGENS; HUMANS; LINKAGE DISEQUILIBRIUM; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; RECEPTORS, IMMUNOLOGIC; RECEPTORS, KIR; SPAIN; YOUNG ADULT;

EID: 70149108927     PISSN: 14664879     EISSN: 14765470     Source Type: Journal    
DOI: 10.1038/gene.2009.34     Document Type: Article

References (53)

1. Compston A, Coles A. Multiple sclerosis. Lancet 2008; 372: 1502-1517.
2. Schmidt H, Williamson D, Ashley-Koch A. HLA-DR15 haplotype and multiple sclerosis: A HuGE review. Am J Epidemiol 2007; 165: 1097-1109.
3. Svejgaard A. The immunogenetics of multiple sclerosis. Immunogenetics 2008; 60: 275-286.
4. Haines JL, Bradford Y, Garcia ME, Reed AD, Neumeister E, Pericak-Vance MA et al. Multiple susceptibility loci for multiple sclerosis. Hum Mol Genet 2002; 11: 2251-2256.
5. Hafler DA, Compston A, Sawcer S, Lander ES, Daly MJ, De Jager PL et al. Risk alleles for multiple sclerosis identified by a genomewide study. N Engl J Med 2007; 357: 851-862.
6. Gregory SG, Schmidt S, Seth P, Oksenberg JR, Hart J, Prokop A et al Interleukin 7 receptor alpha chain (IL7R) shows allelic and functional association with multiple sclerosis. Nat Genet 2007; 39: 1083-1091.
7. Lundmark F, Duvefelt K, Iacobaeus E, Kockum I, Wallstrom E, Khademi M et al. Variation in interleukin 7 receptor alpha chain (IL7R) influences risk of multiple sclerosis. Nat Genet 2007; 39: 1108-1113.
8. Koch S, Goedde R, Nigmatova V, Epplen JT, Muller N, de Seze J et al Association of multiple sclerosis with ILT6 deficiency. Genes Immun 2005; 6: 445-447.
9. Arm JP, Nwankwo C, Austen KF. Molecular identification of a novel family of human Ig superfamily members that possess immunoreceptor tyrosine-based inhibition motifs and homology to the mouse gp49B1 inhibitory receptor. J Immunol 1997; 159: 2342-2349.
10. Borges L, Hsu ML, Fanger N, Kubin M, Cosman D. A family of human lymphoid and myeloid Ig-like receptors, some of which bind to MHC class I molecules. J Immunol 1997; 159: 5192-5196.
11. Colonna M, Navarro F, Bellon T, Llano M, Garcia P, Samaridis J et al A common inhibitory receptor for major histocompatibility complex class I molecules on human lymphoid and myelomonocytic cells. J Exp Med 1997; 186: 1809-1818.
12. Torkar M, Haude A, Milne S, Beck S, Trowsdale J, Wilson MJ. Arrangement of the ILT gene cluster: A common null allele of the ILT6 gene results from a 6.7-kbp deletion. Eur J Immunol 2000; 30: 3655-3662.
13. López-Botet M, Bellón T. Natural killer cell activation and inhibition by receptors for MHC class I. Curr Opin Immunol 1999; 11: 301-307.
14. Lanier LL. Face off - the interplay between activating and inhibitory immune receptors. Curr Opin Immunol 2001; 13: 326-331.
15. Cosman D, Fanger N, Borges L, Kubin M, Chin W, Peterson L et al. A novel immunoglobulin superfamily receptor for cellular and viral MHC class I molecules. Immunity 1997; 7: 273-282.
16. Chapman TL, Heikeman AP, Bjorkman PJ. The inhibitory receptor LIR-1 uses a common binding interaction to recognize class I MHC molecules and the viral homolog UL18. Immunity 1999; 11: 603-613.
17. Valés-Gómez M, Shiroishi M, Maenaka K, Reyburn HT. Genetic variability of the major histocompatibility complex class I homologue encoded by human cytomegalovirus leads to differential binding to the inhibitory receptor ILT2. J Virol 2005; 79: 2251-2260.
18. Kabalak G, Koch S, Dobberstein B, The YH, Matthias T, Schnarr S et al Immunoglobulin-like transcripts as risk genes for autoimmunity. Ann N Y Acad Sci 2007; 1110: 10-14.
19. Wilson MJ, Torkar M, Haude A, Milne S, Jones T, Sheer D et al. Plasticity in the organization and sequences of human KIR/ILT gene families. Proc Natl Acad Sci USA 2000; 97: 4778-4783.
20. Vilches C, Parham P. KIR: Diverse, rapidly evolving receptors of innate and adaptive immunity. Annu Rev Immunol 2002; 20: 217-251.
21. Norman PJ, Parham P. Complex interactions: The immunogenetics of human leukocyte antigen and killer cell immunoglobulin-like receptors. Semin Hematol 2005; 42: 65-75.
22. Parham P. MHC class I molecules and KIRs in human history, health and survival. Nat Rev Immunol 2005; 5: 201-214.
23. Khakoo SI, Carrington M. KIR and disease: A model system or system of models? Immunol Rev 2006; 214: 186-201.
24. Estefanía E, Gómez-Lozano N, Portero F, de Pablo R, Solís R, Sepúlveda S et al. Influence of KIR-gene diversity on the course of HSV-1 infection: Resistance to the disease is associated with the absence of KIR2DL2 and KIR2DS2. Tissue Antigens 2007; 70 34-41.
25. Moretta A, Locatelli F, Moretta L. Human NK cells: From HLA class I-specific killer Ig-like receptors to the therapy of acute leukemias. Immunol Rev 2008; 224: 58-69.
26. Reyburn HT, Mandelboim O, Vales-Gomez M, Davis DM, Pazmany L, Strominger JL. The class I MHC homologue of human cytomegalovirus inhibits attack by natural killer cells. Nature 1997; 386: 514-517.
27. Farrell HE, Davis-Poynter NJ, Andrews DM, Degli-Esposti MA. Function of CMV-encoded MHC class I homologues. Curr Top Microbiol Immunol 2002; 269: 131-151.
28. Gumá M, Angulo A, Lopez-Botet M. NK cell receptors involved in the response to human cytomegalovirus infection. Curr Top Microbiol Immunol 2006; 298: 207-223.
29. Ressing ME, Horst D, Griffin BD, Tellam J, Zuo J, Khanna R et al. Epstein-Barr virus evasion of CD8 and CD4 T cell immunity via concerted actions of multiple gene products. Semin Cancer Biol 2008; 25 25.
30. Pappworth IY, Wang EC, Rowe M. The switch from latent to productive infection in Epstein-Barr virus-infected B cells is associated with sensitization to NK cell killing. J Virol 2007; 81: 474-482.
31. Guerreiro-Cacais AO, Uzunel M, Levitskaya J, Levitsky V. Inhibition of heavy chain and beta2-microglobulin synthesis as a mechanism of major histocompatibility complex class I downregulation during Epstein-Barr virus replication. J Virol 2007; 81: 1390-1400.
32. Christensen T. Human herpesviruses in MS. Int MS J 2007; 14: 41-47.
33. Morandi B, Bramanti P, Bonaccorsi I, Montalto E, Oliveri D, Pezzino G et al. Role of natural killer cells in the pathogenesis and progression of multiple sclerosis. Pharmacol Res 2008; 57: 1-5.
34. Sospedra M, Martin R. Immunology of multiple sclerosis. Annu Rev Immunol 2005; 23: 683-747.
35. Lunemann JD, Kamradt T, Martin R, Munz C. Epstein-Barr virus: environmental trigger of multiple sclerosis? J Virol 2007; 81 6777-6784.
36. Serafini B, Rosicarelli B, Franciotta D, Magliozzi R, Reynolds R, Cinque P et al. Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain. J Exp Med 2007; 204: 2899-2912.
37. Friese MA, Jakobsen KB, Friis L, Etzensperger R, Craner MJ, McMahon RM et al. Opposing effects of HLA class I molecules in tuning autoreactive CD8+ T cells in multiple sclerosis. Nat Med 2008; 14: 1227-1235.
38. Pericak-Vance MA, Rimmler JB, Martin ER, Haines JL, Garcia ME, Oksenberg JR et al. Linkage and association analysis of chromosome 19q13 in multiple sclerosis. Neurogenetics 2001; 3: 195-201.
39. Yeo TW, De Jager PL, Gregory SG, Barcellos LF, Walton A, Goris A et al. A second major histocompatibility complex susceptibility locus for multiple sclerosis. Ann Neurol 2007; 61: 228-236.
40. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50: 121-127.
41. Hirayasu K, Ohashi J, Kashiwase K, Takanashi M, Satake M, Tokunaga K et al. Long-term persistence of both functional and non-functional alleles at the leukocyte immunoglobulin-like receptor A3 (LILRA3) locus suggests balancing selection. Hum Genet 2006; 119: 436-443.
42. Green A. The epidemiologic approach to studies of association between HLA and disease. II. Estimation of absolute risks, etiologic and preventive fraction. Tissue Antigens 1982; 19: 259-268.
43. Consortium IMSG. Refining genetic associations in multiple sclerosis. Lancet Neurol 2008; 7: 567-569.
44. Kotsch K, Wehling J, Blasczyk R. Sequencing of HLA class II genes based on the conserved diversity of the non-coding regions: Sequencing based typing of HLA-DRB genes. Tissue Antigens 1999; 53: 486-497.
45. Svejgaard A, Ryder LP. HLA and disease associations: Detecting the strongest association. Tissue Antigens 1994; 43: 18-27.
46. Vilches C, Castaño J, Gómez-Lozano N, Estefanía E. Facilitation of KIR genotyping by a PCR-SSP method that amplifies short DNA fragments. Tissue Antigens 2007; 70: 415-422.
47. Norman PJ, Cook MA, Carey BS, Carrington CV, Verity DH, Hameed K et al. SNP haplotypes and allele frequencies show evidence for disruptive and balancing selection in the human leukocyte receptor complex. Immunogenetics 2004; 56: 225-237.
48. Sawcer S, Ban M, Maranian M, Yeo TW, Compston A, Kirby A et al. A high-density screen for linkage in multiple sclerosis. Am J Hum Genet 2005; 77: 454-467.
49. Yeo TW, Roxburgh R, Maranian M, Singlehurst S, Gray J, Hensiek A et al. Refining the analysis of a whole genome linkage disequilibrium association map: The United Kingdom results. J Neuroimmunol 2003; 143: 53-59.
50. Abecasis GR, Noguchi E, Heinzmann A, Traherne JA, Bhattacharyya S, Leaves NI et al. Extent and distribution of linkage disequilibrium in three genomic regions. Am J Hum Genet 2001; 68: 191-197.
51. Dunning AM, Durocher F, Healey CS, Teare MD, McBride SE, Carlomagno F et al. The extent of linkage disequilibrium in four populations with distinct demographic histories. Am J Hum Genet 2000; 67: 1544-1554.
52. Bonetti A, Koivisto K, Pirttila T, Elovaara I, Reunanen M, Laaksonen M et al. A follow-up study of chromosome 19q13 in multiple sclerosis susceptibility. J Neuroimmunol 2009; 208: 119-124.
53. Yawata M, Yawata N, Abi-Rached L, Parham P. Variation within the human killer cell immunoglobulin-like receptor (KIR) gene family. Crit Rev Immunol 2002; 22: 463-482.